Person: SAĞLIK, İMRAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SAĞLIK
First Name
İMRAN
Name
16 results
Search Results
Now showing 1 - 10 of 16
Publication Evaluation of diagnostic performance of bd max ebp assay in patients with diarrheal illness(Pera Yayıncılık Hizmetleri, 2022-12-01) Özyurt, Özlem Koyuncu; Saglik, İmran; Özhak, Betül; Mutlu, Derya; Levent, Belkıs; Dönmez, Levent; Ongut, Gözde; Çolak, Dilek; Oğunç, Dilara; SAĞLIK, İMRAN; Tıp Fakültesi; Tıbbi Mikrobiyoloji Ana Bilim Dalı; 0000-0003-0864-4989 ; A-4970-2019Objective: Detection of the etiological agents in patients with acute diarrhea is challenging due to a wide variety of pathogens. The aim of this study is to evaluate the diagnostic performance of BD Max Enteric Bacterial Pathogens (EBP) PCR assay in patients with diarrheal illness.Methods: Between 1 January 2014 and 31 May 2015, stool samples from pediatric or adult patients with diarrhea submitted for routine analysis of bacterial stool pathogens were included in the study. We compared the BD Max EBP PCR assay to culture for the detection of Salmonella spp., Shigella spp., Campylobacter jejuni, and Campylobacter coli and an EIA for Shiga toxins 1 and 2. Discordant results were adjudicated by either antigen detection methods or Film array GI Panel.Results: When coinfections were excluded, the positive percent agreement values for the BD Max EBP assay (PPA) was 100% and negative percent agreement (NPA) was between 98.0%-99.7%, when compared with culture and EIA. After discrepant analysis, the PPA values for the BD Max EBP assay was 100% and NPA was between 99.5%-100%.Conclusion: The BD Max EBP assay showed a high correlation rate with conventional and molecular methods for the detection of stool pathogens.Publication Evaluation of the two different real time polymerase chain reaction methods used for bk virus (bkv) quantification and bkv genotype assignment(Ankara Microbiology Soc, 2019-07-01) Erman Daloğlu, Aylin; Mutlu, Derya; Can Sarınoğlu, Rabia; Mutlu, Esvet; Niesters, Hubert G. M.; Çolak, Dilek; SAĞLIK, İMRAN; 0000-0003-0120-3830; 0000-0002-6786-137X; 0000-0001-9222-8659; 0000-0002-1758-0430; H-1307-2018; AAH-6808-2019; A-4970-2019; C-9377-2018; U-8647-2019BK virus (BKV) viral load quantification has a distinct role in the clinical control of BKV nephropathy and organ rejection among renal transplant recipients. In this study, it was aimed to compare BKV DNA measurement values performed with two different real-time polymerase chain reaction (PCR) methods and to determine BKV genotypes in renal transplant recipients. Totally, 150 clinical samples tested previously in two different laboratories (Lab-1 and Lab-2) from adult and pediatric renal transplantation patients were included in the study. Fifty plasma samples of 50 different patients from Lab-1, 50 plasma and 50 urine samples of 58 different patients from Lab-2 were included in the study. Viral nucleic acid extraction was performed with automatized systems in Lab-1 and Lab-2 (EZ1, Qiagen, Germany and MagNA Pure 96, Roche Diagnostics, Germany; respectively;). Real-time PCR procedure was carried out in Lab-1 with an amplification mixture of primer, probe sequences targeting VP-1 gene region using RotorGene (Qiagen, Germany) and in Lab-2 with an amplification mixture of primer, probe sequences targeting VP-2 gene region using ABI Prism 7500 (Applied Biosystems, USA). BKV genotyping was performed with multiplex PCR using primer, probe sequences for BKV genotypes I-IV. In both of the laboratories, 82 (54.6%) of the samples were found as positive, 37(24.6%) samples were found as negative and a moderate agreement was found between qualitative results of two real-time PCR methods (k= 0.56, p< 0.001). Median viral load values were 4.1 x 10(4) copies/ml (321-6 x 10(9)) in Lab-1 and 3.3 x 10(5) copies/ml (224-8.3 x 10(10)) in Lab-2 for positive samples. According to the lineer regression analysis of quantitative results, moderate (R-2 = 0.52, p< 0.001) and high (R-2 = 0.88, p< 0.001) correlation was found for plasma (n= 52) and urine (n= 30) samples, respectively. Bland-Altman analysis yielded a mean difference of -0.58 log(10) for all samples. For plasma samples mean difference was -0.29 log(10), while it was -1.1 log(10 )for urine samples. In all samples, Lab-1 measurements were lower than Lab-2 measurements. A mean difference of -1.1 log(10) indicated that the measurement values of Lab-2 were more higher than Lab-1 measurments with an average of 1.1 log(10). Supporting this result, 71.9% of the samples had a measurement difference more than 0.5 log 10 and 29.2% of the samples had a measurement difference more than 1 log(10). Only 28.1% of the samples were measured within clinically acceptable log difference range (less than 0.5 log(10)).BKV genotyping was performed only for 74 different patient samples with sufficient copy numbers and genotype I (81.7%), IV (15.5%), II (1.4%), I+IV (1.4%) were detected. When the results were compared; 66.6% (n= 12) of the genotype IV samples had more than 1 log(10) and 83.3% of them had more than 0.5 log(10) viral load measurement difference. Correlation and linear regression analyzes were insufficient for the comparison of the results of the two different tests. It will be appropriate for each center to monitor patients with the same test until the international BKV standard developed by the World Health Organization is optimized. The clinical correlation of the tests is limited to the currently used test. The result of incorrect BKV quantification affects the clinical decision. Measurements less than the actual value will lead to the development of BKV nephropathy, and higher measurements will lead to unnecessary allograft biopsy and unnecessary reduction of immunosuppression.Publication Development and validation of a simple risk scoring system for a COVİD-19 diagnostic prediction model(Tüberküloz ve Toraks, 2023-01-01) Güçlü, Özge Aydın; Ursavaş, Ahmet; Ocakoğlu, Gokhan; Demirdogen, Ezgi; Öztürk, Nilufer Aylin Acet; Topçu, Dilara Ömer; Terzi, Orkun Eray; Onal, Uğur; Dilektaşlı, Aslı Görek; Sağlık, İmran; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; AkalIn, Halis; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; OCAKOĞLU, GÖKHAN; DEMİRDÖĞEN, EZGİ; ACET ÖZTÜRK, NİLÜFER AYLİN; ÖMER TOPÇU, DİLARA; TERZİ, ORKUN ERAY; ÖNAL, UĞUR; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; AkalIn, Halis; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0003-1005-3205; 0000-0002-1114-6051; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-2954-4293; 0000-0001-7530-1279; 0000-0002-9027-1132; AAH-5180-2021; A-4970-2019; AAG-8744-2021; AAI-3169-2021; JCO-3678-2023; JPK-7012-2023Introduction: In a resource-constrained situation, a clinical risk stratification system can assist in identifying individuals who are at higher risk and should be tested for COVID-19. This study aims to find a predictive scoring model to estimate the COVID-19 diagnosis.Materials and Methods: Patients who applied to the emergency pandemic clinic between April 2020 and March 2021 were enrolled in this retrospective study. At admission, demographic characteristics, symptoms, comorbid diseases, chest computed tomography (CT), and laboratory findings were all recorded. Development and validation datasets were created. The scoring system was performed using the coefficients of the odds ratios obtained from the multivariable logistic regression analysis.Results: Among 1187 patients admitted to the hospital, the median age was 58 years old (22-96), and 52.7% were male. In a multivariable analysis, typical radiological findings (OR= 8.47, CI= 5.48-13.10, p< 0.001) and dyspnea (OR= 2.85, CI= 1.71-4.74, p< 0.001) were found to be the two important risk factors for COVID-19 diagnosis, followed by myalgia (OR= 1.80, CI= 1.082.99, p= 0.023), cough (OR= 1.65, CI= 1.16-2.26, p= 0.006) and fatigue symptoms (OR= 1.57, CI= 1.06-2.30, p= 0.023). In our scoring system, dyspnea was scored as 2 points, cough as 1 point, fatigue as 1 point, myalgia as 1 point, and typical radiological findings were scored as 5 points. This scoring system had a sensitivity of 71% and a specificity of 76.3% for a cut-off value of >2, with a total score of 10 (p< 0.001).Conclusion: The predictive scoring system could accurately predict the diagnosis of COVID-19 infection, which gave clinicians a theoretical basis for devising immediate treatment options. An evaluation of the predictivePublication Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection(Springer London Ltd, 2022-01-20) Türkkan, Alpaslan; Sağlık, İmran; Turan, Cansu; Şahin, Ahmet; Akalın, Halis; Ener, Beyza; Kara, Ateş; Çelebi, Solmaz; Şahin, Emre; Hacımustafaoğlu, Mustafa; TÜRKKAN, ALPASLAN; SAĞLIK, İMRAN; TURAN, CANSU; AKALIN, EMİN HALİS; ENER, BEYZA; ÇELEBİ, SOLMAZ; ŞAHİN, EMRE; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Tıp Fakültesi; Halk Sağlığı Ana Bilim Dalı; 0000-0003-0864-4989; 0000-0003-3146-6391; 0000-0002-4415-076X; 0000-0001-7530-1279; 0000-0002-1654-3232; 0000-0003-4646-660X; GFL-2282-2022; GCM-3391-2022; IVB-4013-2023; AAU-8952-2020; CNK-0895-2022; ENK-4130-2022; JFP-8395-2023; CTG-5805-2022Background The continual course of the pandemic points to the importance of studies on the rate and durability of protective immunity after infection or vaccination. Aims In this study, we aimed to monitor anti-nucleocapsid (N) and anti-spike (S) antibodies against SARS-CoV-2 nearly 9 months duration after infection. Methods Anti-nucleocapsid (N) (at 11-15-20-29-38 weeks) and anti-spike antibodies (at 11 and 38 weeks) against SARS-CoV-2 were monitored during 38 weeks after the initial symptoms of COVID-19. Results Of 37 cases between 18 and 57 years old, 54% were women. The findings showed that anti-N antibodies decreased significantly after the 15th week (between 15 and 20 weeks, p = 0.016; 20-29 weeks, p = 0.0009; and 29-38 weeks, p = 0.049). At the 38th week, mean antibody levels decreased 35% compared to the 11th week, and 8% of the cases turned negative results. Anti-N antibody average level was 56.48 on the 11th week (the cut-off index threshold >= 1). It was estimated statistically that it would decrease to an average of 20.48 in weeks 53-62. In females, average antibody levels of all measurements were lower than males (p > 0.05). Anti-S antibody levels 14% increased at 38th week compared to 11th week (quantitative positivity threshold >= 0.8 U/ml), and no cases were negative at 38th week. Conclusions Patients had >= 90% positivity after at least 9 months of symptoms, both anti-N and anti-S antibodies. In all samples, both anti-N and anti-S antibody levels were lower in females. The findings suggest that the quantitative values of anti-S antibodies remained high for at least 9 months and could provide protection.Publication Tocilizumab treatment in covid-19: A prognostic study using propensity score matching(Wroclaw Medical Univ, 2022-08-11) Güçlü, Özge Aydın; Önal, Uğur; Akalın, Halis; Öztürk, Nilüfer Aylin Acet; Belik, Hazel Öztürk; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Kazak, Esra; Ocakoğlu, Gökhan; Sağlık, İmran; Coşkun, Funda; Ediger, Dane; Heper, Yasemin; Ursavaş, Ahmet; Yılmaz, Emel; Uzaslan, Esra; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; ÖNAL, UĞUR; AKALIN, EMİN HALİS; ACET ÖZTÜRK, NİLÜFER AYLİN; ÖZTÜRK BELİK, HAZEL; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; KAZAK, ESRA; OCAKOĞLU, GÖKHAN; SAĞLIK, İMRAN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; HEPER, YASEMİN; URSAVAŞ, AHMET; YILMAZ, EMEL; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Tıp Fakültesi; 0000-0003-1005-3205; 0000-0001-6194-3254; 0000-0001-7530-1279; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0002-1114-6051; 0000-0003-0864-4989; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0003-1785-3539; 0000-0002-9027-1132; AAG-8744-2021; AAD-1271-2019; JCO-3678-2023; AAH-5180-2021; JPK-7012-2023; ACQ-7832-2022; AAU-8952-2020; AAI-3169-2021; AAG-9930-2019; Z-1424-2019; GQC-6764-2022; DTT-7416-2022Background. The potential role of interleukin-6 (IL-6) in coronavirus disease 2019 (COVID-19) pneumonia provides the rationale for investigating IL-6 signaling inhibitors.Objectives. To evaluate and report treatment responses to tocilizumab (TCZ) in COVID-19 patients and compare mortality outcomes with those of standard care.Materials and methods. Patients hospitalized with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, diagnosed with reverse transcription polymerase chain reaction (RT-PCR) between March 2020 and April 2021, were enrolled in this single-center retrospective cohort study. Propensity score matching was performed in order to reduce confounding effects secondary to imbalances in receiving TCZ treatment.Results. A total of 364 patients were included in this study. Two hundred thirty-six patients received standard care, while 128 patients were treated with TCZ in addition to standard care (26 (20.3%) patients received a dose of 400 mg intravenously once, while 102 (79.7%) patients received a total dose of 800 mg intravenously). In the propensity score-matched population, less noninvasive mechanical ventilation (p = 0.041) and mechanical ventilation support (p = 0.015), and fewer deaths (p = 0.008) were observed among the TCZ-treated patients. The multivariate adjusted Cox regression model showed a significantly higher survival rate among TCZ patients compared to controls (hazard ratio (HR): 0.157, 95% confidence interval (95% CI): 0.026-0.951; p = 0.044). The hazard ratio for mortality in the TCZ group was 0.098 (95% CI: 0.030-0.318; p = 0.0001 using log-rank test).Conclusions. This study determined that TCZ treatment in COVID-19 patients was associated with better survival, reduced need for mechanical ventilation and reduced hospital-associated mortality.Publication Prognostic factors for COVID-19 patients(J Infection Developing Countries, 2022-03-01) Önal, Uğur; Güçlü, Özge Aydın; Akalın, Halis; Öztürk, Nilüfer Aylin Acet; Semet, Cihan; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Sağlık, İmran; Kazak, Esra; Özkaya, Güven; Coşkun, Funda; Ediger, Dane; Heper, Yasemin; Ursavaş, Ahmet; Yılmaz, Emel; Uzaslan, Esra; Karadağ, Mehmet; ÖNAL, UĞUR; AYDIN GÜÇLÜ, ÖZGE; AKALIN, EMİN HALİS; ACET ÖZTÜRK, NİLÜFER AYLİN; SEMET, CİHAN; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; KAZAK, ESRA; ÖZKAYA, GÜVEN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; HEPER, YASEMİN; URSAVAŞ, AHMET; YILMAZ, EMEL; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Tıp Fakültesi; Mikrobiyoloji Ana Bilim Dalı; 0000-0001-6194-3254; 0000-0003-1005-3205; 0000-0001-7530-1279; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-0864-4989; 0000-0003-0297-846X; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0002-3894-1231; 0000-0002-9027-1132; A-4421-2016; AAG-8459-2021; GCM-3391-2022; DTT-7416-2022; AAH-9812-2021; AEA-4817-2022; Z-1424-2019; AAU-8952-2020; AAG-9930-2019; ACQ-7832-2022; AAD-1271-2019; AAE-9142-2019; CTY-9474-2022; AAI-3169-2021; HJZ-6992-2023; CDI-1977-2022; AAG-8744-2021Introduction: Determining prognostic factors in patients with coronavirus disease (COVID-19) can have great impact on treatment planning and follow-up strategies. Herein, we aimed to evaluate prognostic factors and clinical scores for confirmed COVID-19 patients in a tertiary care hospital in the Bursa region of Turkey. Methodology: Patients who had been diagnosed with COVID-19 microbiologically and/or radiologically between March and October 2020 in a tertiary-care university hospital were enrolled retrospectively. Adult patients (>= 18 years) with a clinical spectrum of moderate, severe, or critical illness were included. The dependent variable was 30-day mortality and logistic regression analysis was used to evaluate any variables with a significant p value (< 0.05) in univariate analysis. Results: A total of 257 patients were included in the study. The mortality rate (30-day) was 14.4%. In logistic regression analysis, higher scores on sequential organ failure assessment (SOFA) (p < 0.001, odds ratio (OR) = 1.86, 95% CI = 1.42-2.45) and CURB-65 pneumonia severity criteria (p = 0.001, OR = 2.60, 95% CI = 1.47-4.57) were found to be significant in predicting mortality at admission. In deceased patients, there were also significant differences between the baseline, day-3, day-7, and day-14 results of D-dimer (p = 0.01), ferritin (p = 0.042), leukocyte (p = 0.019), and neutrophil (p = 0.007) counts. Conclusions: In our study of COVID-19 patients, we found that high SOFA and CURB-65 scores on admission were associated with increased mortality. In addition, D-dimer, ferritin, leukocyte and neutrophil counts significantly increased after admission in patients who died.Publication Association of SARS-CoV-2 cycle threshold (Ct) values with clinical course and serum biomarkers in COVID-19 patients(J Infection Developing Countries, 2022-03-01) Sağlık, İmran; Ener, Beyza; Akalın, Halis; Özdemir, Buşra; Ocakoğlu, Gökhan; Yalçın, Barış; Onal, Uğur; Güçlü, Özge Aydın; Öztürk, Nilüfer Aylin Acet; Tüzemen, Ülku; Demirdoğen, Ezgi; Dilektaşlı, Asli Görek; Ağca, Harun; Kazak, Esra; Coşkun, Funda; Heper, Yasemin; Payaslıoğlu, Melda; Ediger, Dane; Ursavaş, Ahmet; Yılmaz, Emel; Özakin, Cüneyt; Uzaslan, Esra; Karadağ, Mehmet; SAĞLIK, İMRAN; ENER, BEYZA; AKALIN, EMİN HALİS; OCAKOĞLU, GÖKHAN; ÖNAL, UĞUR; AYDIN GÜÇLÜ, ÖZGE; ACET ÖZTÜRK, NİLÜFER AYLİN; TÜZEMEN, NAZMİYE ÜLKÜ; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; AĞCA, HARUN; KAZAK, ESRA; COŞKUN, NECMİYE FUNDA; HEPER, YASEMİN; PAYASLIOĞLU, AYŞE MELDA; EDİGER, DANE; URSAVAŞ, AHMET; YILMAZ, EMEL; ÖZAKIN, CÜNEYT; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0003-0864-4989; 0000-0001-7530-1279; 0000-0002-1114-6051; 0000-0001-6194-3254; 0000-0003-1005-3205; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0002-2651-2034; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0002-3894-1231; 0000-0001-5428-3630; 0000-0002-9027-1132; AAD-1271-2019; ISU-9626-2023; ACQ-7832-2022; JCO-3678-2023; AAI-3169-2021; AAU-8952-2020; AAH-5180-2021; AAG-8744-2021; JPK-7012-2023; A-4970-2019Introduction: Our knowledge has gaps regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication levels and its association to severity of Coronavirus disease 2019 (COVID-19). The aim of this study was to investigate the association of SARS-CoV-2 viral load with disease severity and serum biomarkers in COVID-19 patients. Methodology: Viral load was determined via cycle threshold (Ct) values of SARS-CoV-2 real-time reverse transcriptase-polymerase chain reaction (RT-PCR) in 214 adult patients. Ct values were compared with clinical severity, biochemical and hematological biomarkers. Results: Clinical course of the disease was mild (49.1%), moderate (40.2%), and severe (10.7%). Median Ct value was 28.2 (IQR: 22.2-33.8) during the first week of the disease. Ct values were lower within five days after symptom onset [lowest Ct value on the third day (median: 24, IQR: 20.6-32.3)], but they increased significantly during the second and third weeks. No association was detected between admission Ct values and disease severity. Gender, age, co-morbidity, and mortality did not differ significantly in patients with low (<= 25) and high (> 25) Ct values. White blood cell, neutrophil, platelet, and especially lymphocyte counts, were significantly lower in patients with low Ct values. Conclusions: No definitive/clear correlation between SARS-CoV-2 viral load and severity and mortality was found in the studied COVID-19 patients. However, neutrophil, platelet, and especially lymphocyte count were significantly lower in patients with a high viral load.Publication Effect of oral antiseptics on the viral load of sars-cov-2: A randomized controlled trial(Wroclaw Medical Univ, 2022-07-29) Gül, Sema Nur Sevinç; Dilsiz, Alparslan; Aydın, Nurten Nur; Sağlık, İmran; SAĞLIK, İMRAN; Tıp Fakültesi; Mikrobiyoloji Ana Bilim Dalı; 0000-0003-0699-917X; 0000-0003-0864-4989; 0000-0003-4138-2490; AAD-5712-2019; A-4970-2019Background. In the oral cavity, which plays an important role in the transmission of severe acute respira-tory syndrome coronavirus 2 (SARS-CoV-2), it is possible to reduce the viral load of SARS-CoV-2 with antiseptics, thereby minimizing the transmission of the virus during dental procedures.Objectives.The aim of this study was to clinically evaluate the effect of the hypochlorous acid (HClO) and povidone-iodine (PVP-I) solutions on the oral viral load of SARS-CoV-2.Material and methods.This randomized controlled trial was conducted on 75 patients hospitalized in the COVID-19 ward of a local hospital. All the patients included in the study were within the first 24 h of hospitalization and the first 5 days of coronavirus disease 2019 (COVID-19) symptoms. The viral load of mouthwash samples was measured with the cycle threshold (Ct) value of SARS-CoV-2 through a real-time reverse transcription polymerase chain reaction (RT-PCR). The patients were divided into 3 groups. The effect on the patient's SARS-CoV-2 viral load was investigated after gargling the mouths and throats for 30 s with HClO, PVP-I and isotonic saline. First, a sample was taken after gargling with isotonic saline, then another sample was taken after gargling for 30 s with a particular antiseptic to determine the viral load of SARS-CoV-2.Results. Comparing the before and after mouthwash samples from all 3 groups, there were no statistically significant differences in the Ctvalues before and after gargling (p > 0.05). However, there were statisti-cally significant differences in the number of negative samples after the use of HClO and PVP-I, which were positive before gargling (p < 0.05).Conclusions. In the light of the data obtained in this study, there is insufficient evidence that gargling with HClO or PVP-I reduces viral load. Taken together, these findings imply no role for antiseptics in the transmission of SARS-CoV-2 by the aerosol generated during dental procedures, or more generally, SARS-CoV-2 infection control.Publication Follow-up of human adenovirus viral load in pediatric hematopoietic stem cell transplant recipients(Wiley, 2021-01-16) Peker, Bilal Olcay; Kıntrup, Gülen Tüysüz; Sağlık, İmran; Sarinoğlu, Rabia Can; Güler, Elif; Mutlu, Derya; Küpesiz, Osman Alphan; Çolak, Dilek; SAĞLIK, İMRAN; Tıp Fakültesi; Tıbbi Mikrobiyoloji Ana Bilim Dalı; 0000-0003-0864-4989; A-4970-2019; GCM-3391-2022Background: The spectrum of human adenovirus (HAdV)-related disease is broad, and the virus acts on many organs and systems in hematopoietic stem cell transplantation (HSCT) recipients. We aimed to evaluate the effect of HAdV-DNA positivity with clinical and laboratory findings 4 months after HSCT.Methods and results: We retrospectively investigated HAdV-DNA in 153 HSCT recipients (<= 18 years) by quantitative real-time polymerase chain reaction (RealStar; Altona Diagnostics). The results of samples from January 2014 to December 2017 are included. HAdV-DNA was positive for at least one sample type in 50 (32.67%) patients. HAdV-DNA positivity rate was 8.92% (N: 145/1625), 40.25% (N: 64/159), and 25% (N: 2/8) for plasma, stool, and urine samples, respectively. HAdV-DNA was positive in the plasma of 38 (24.83%) patients at a median 16 (range: 1-58 days) days after HSCT. The mortality rate was 23.68% and 6.95% in plasma HAdV-positive and HAdV-negative patients (p = .014). Moreover, HAdV-DNA positivity had an impact on overall survival for allogeneic-HSCT (p = .013), with the cumulative effect including graft-versus-host disease state in multivariate analysis (p = .014).Conclusions: Plasma HAdV-DNA positivity is a potential influencer that decreases survival in the early post-transplant period. Due to the high mortality rates, close monitoring is required of HAdV infections after HSCT with sensitive methods, especially at the early stage.Publication Comparison of SARS-CoV-2 antibodies and six immunoassays in pediatric and adult patients 12 weeks after COVID-19(Springernature, 2022-02-14) Sağlık, Imran; Türkkan, Alparslan; Turan, Cansu; Kara, Ateş; Akalın, Halis; Ener, Beyza; Şahin, Ahmet; Yeşil, Edanur; Çelebi, Solmaz; Kazak, Esra; Heper, Yasemin; Yılmaz, Emel; Korkmaz, Muhammet Furkan; Türe, Esra; Hacımustafaoğlu, Mustafa; SAĞLIK, İMRAN; Türkkan, Alparslan; TURAN, CANSU; AKALIN, EMİN HALİS; ENER, BEYZA; ÇELEBİ, SOLMAZ; KAZAK, ESRA; HEPER, YASEMİN; YILMAZ, EMEL; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Tıp Fakültesi; Tıbbi Mikrobiyoloji Ana Bilim Dalı; GCM-3391-2022; CDH-6078-2022; IVB-4013-2023; AAU-8952-2020; CNK-0895-2022; ENK-4130-2022; AAG-8459-2021; CTY-9474-2022; GDP-0005-2022; CTG-5805-2022IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients' characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens.MethodsThis prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies.ResultsThe findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001).ConclusionOverall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity ( 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies.